Mostrando 6 resultados de: 6
Filtros aplicados
Publisher
Biotecnologia Aplicada(2)
BMC Cancer(1)
British Journal of Cancer(1)
Cancer Research(1)
Molecular and Cellular Biochemistry(1)
Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2)
ArticleAbstract: Protein Kinase (casein kinase 2, CK2) is a serine-threonine kinase that is frequently dysregulated iPalabras claves:Autores:Acevedo B.E., Alonso D.F., Falcón-Cama V., López-Mola E., Mendoza O., Perea-Rodríguez S.E., Puchades Y., Reyes O., Santiago Nelson Vispo, Santos-Savio A., Silva R., Torrens I.Fuentes:scopusA modified variant of human Interleukin-15 as a novel antigen for active immunotherapy in rheumatoid arthritis
ReviewAbstract: Interleukin (IL)-15 is a pro-inflammatory cytokine that plays a crucial role in the pathogenesis ofPalabras claves:IL-15, Immunization, neutralizing antibodies, non-human primates, Rheumatoid ArthritisAutores:Alexey Llópiz-Arzuaga, Arrieta C.A., Besada-Pérez V., Castro-Velazco J., Eugenio Hardy, Geronimo H., Guillén-Nieto G.E., Martínez K., Martínez-Castillo R., Morera-Díaz Y., Moro A., Perea-Rodríguez S.E., Puente P., Ramos Y., Rodríguez-Álvarez Y., Santos-Savio A., Silva R., Vázquez M.Fuentes:scopusCIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo
ArticleAbstract: Protein Kinase CK2 is a serine-threonine kinase frequently deregulated in many human tumors. Here, wPalabras claves:apoptosis, Cancer targeted therapy, Casein kinase 2Autores:Acevedo B.E., Alonso D.F., Ariosa J., Bacardí D.M., Baladron I., Besada-Pérez V., Betancourt L., Castellanos L.R., Cosme K., Cruz M., Díaz A., Falcón-Cama V., Farina H., Garay H.E., Gil J., Gómez D., Gómez R., González L.J., Hernández I., Herrera L., López C., López-Mola E., López-Saura P.A., Marcelo J.L., Mendoza O., Perea-Rodríguez S.E., Perera Y., Puchades Y., Reyes O., Rodriguez A., Sánchez A., Santana A., Serrano J.M., Sigman H., Silva R., Solares M., Thelvia I. Ramos Gómez, Valenzuela-Silva C.M.Fuentes:googlescopusOptimizing CIGB-300 intralesional delivery in locally advanced cervical cancer
ArticleAbstract: Background:We conducted a phase 1 trial in patients with locally advanced cervical cancer by injectiPalabras claves:B23/nucleophosmin, Cervical Cancer, CIGB-300, tumour uptakeAutores:Acevedo B.E., Alonso D.F., Ancízar J.A., Baladron I., Casacó C.A., Coca M.A., García I., Gómez R., González L.J., González Y.M., Hernández I., I. Howland-Álvarez, López-Saura P.A., Martínez Y.M., Molina L., Perea-Rodríguez S.E., Perera A., Perera Y., Prats A., Reyes V., Solares M., Torres L.A., Valenzuela-Silva C.M.Fuentes:scopusIdentification of the first antagonist peptide that inhibits biological effects of interleukin-15
ArticleAbstract: Interleukin-15 (IL-15) is a pro-inflammatory cytokine that is expressed in several autoimmune and inPalabras claves:Alpha receptor, antagonist, Cytokine, IL-15, peptideAutores:Alexey Llópiz-Arzuaga, Altruda F., Ancisar J.A., Arrieta C.A., Cabrales A., Chico A., Estévez M., Garay H.E., Geronimo H., Guillén-Nieto G.E., Machado A.C., Noda J., Ojeda M., Perea-Rodríguez S.E., Reyes O., Rodríguez-Álvarez Y., Sánchez A., Santos-Savio A., Silengo L., Suaréz J., Vázquez M.Fuentes:googlescopusSafety and preliminary efficacy data of a novel Casein Kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies
ArticleAbstract: Background: Cervical cancer is now considered the second leading cause of death among women worldwidPalabras claves:Autores:Acevedo B.E., Alonso D.F., Baladron I., Castillo D., Díaz A., Gómez R., González C.A., Herrera L., López-Saura P.A., Perea-Rodríguez S.E., Santana A., Sigman H., Solares A.M., Thelvia I. Ramos Gómez, Valenzuela-Silva C.M.Fuentes:googlescopus